CN102775338B - 全反式维甲酸合成方法 - Google Patents
全反式维甲酸合成方法 Download PDFInfo
- Publication number
- CN102775338B CN102775338B CN201110124227.3A CN201110124227A CN102775338B CN 102775338 B CN102775338 B CN 102775338B CN 201110124227 A CN201110124227 A CN 201110124227A CN 102775338 B CN102775338 B CN 102775338B
- Authority
- CN
- China
- Prior art keywords
- acid
- reaction
- formula
- isomerization reaction
- pdcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000010189 synthetic method Methods 0.000 title abstract description 7
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 title abstract description 4
- 229930002330 retinoic acid Natural products 0.000 title abstract description 4
- 238000006317 isomerization reaction Methods 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 22
- 238000007239 Wittig reaction Methods 0.000 claims abstract description 12
- 239000002585 base Substances 0.000 claims abstract description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical class C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 150000002941 palladium compounds Chemical class 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 239000003513 alkali Substances 0.000 claims abstract description 5
- LDHQCZJRKDOVOX-IHWYPQMZSA-N isocrotonic acid Chemical compound C\C=C/C(O)=O LDHQCZJRKDOVOX-IHWYPQMZSA-N 0.000 claims abstract description 5
- 230000000694 effects Effects 0.000 claims abstract description 4
- 238000007039 two-step reaction Methods 0.000 claims abstract description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 27
- 239000002253 acid Substances 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 229910002666 PdCl2 Inorganic materials 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 7
- 229910052763 palladium Inorganic materials 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 229960000583 acetic acid Drugs 0.000 claims description 3
- -1 alkali metal salt Chemical class 0.000 claims description 3
- OKDHIPXOBPPHTG-UHFFFAOYSA-L benzonitrile;dibromopalladium Chemical compound Br[Pd]Br.N#CC1=CC=CC=C1.N#CC1=CC=CC=C1 OKDHIPXOBPPHTG-UHFFFAOYSA-L 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 claims description 3
- 239000000376 reactant Substances 0.000 claims description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 2
- 229910021605 Palladium(II) bromide Inorganic materials 0.000 claims description 2
- 229910021606 Palladium(II) iodide Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 239000012362 glacial acetic acid Substances 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 229910000000 metal hydroxide Inorganic materials 0.000 claims description 2
- 150000004692 metal hydroxides Chemical class 0.000 claims description 2
- INIOZDBICVTGEO-UHFFFAOYSA-L palladium(ii) bromide Chemical compound Br[Pd]Br INIOZDBICVTGEO-UHFFFAOYSA-L 0.000 claims description 2
- HNNUTDROYPGBMR-UHFFFAOYSA-L palladium(ii) iodide Chemical compound [Pd+2].[I-].[I-] HNNUTDROYPGBMR-UHFFFAOYSA-L 0.000 claims description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 2
- 239000012071 phase Substances 0.000 claims description 2
- 239000001117 sulphuric acid Substances 0.000 claims description 2
- 235000011149 sulphuric acid Nutrition 0.000 claims description 2
- RXJKFRMDXUJTEX-UHFFFAOYSA-N triethylphosphine Chemical compound CCP(CC)CC RXJKFRMDXUJTEX-UHFFFAOYSA-N 0.000 claims description 2
- 239000003643 water by type Substances 0.000 claims description 2
- GPNDARIEYHPYAY-UHFFFAOYSA-N palladium(II) nitrate Inorganic materials [Pd+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O GPNDARIEYHPYAY-UHFFFAOYSA-N 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 22
- 238000006243 chemical reaction Methods 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 239000013067 intermediate product Substances 0.000 abstract description 3
- 150000003284 rhodium compounds Chemical class 0.000 abstract description 2
- UBMLKGCOROJNMF-UHFFFAOYSA-N 1,6,6-trimethylcyclohexene Chemical compound CC1=CCCCC1(C)C UBMLKGCOROJNMF-UHFFFAOYSA-N 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- PMJHHCWVYXUKFD-UHFFFAOYSA-N pentadiene group Chemical group C=CC=CC PMJHHCWVYXUKFD-UHFFFAOYSA-N 0.000 abstract 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 5
- 229910052703 rhodium Inorganic materials 0.000 description 5
- 239000010948 rhodium Substances 0.000 description 5
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000006396 nitration reaction Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- SSVFMICWXDVRQN-UHFFFAOYSA-N ethanol;sodium Chemical compound [Na].CCO SSVFMICWXDVRQN-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- JILPJDVXYVTZDQ-UHFFFAOYSA-N lithium methoxide Chemical compound [Li+].[O-]C JILPJDVXYVTZDQ-UHFFFAOYSA-N 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- WQKGAJDYBZOFSR-UHFFFAOYSA-N potassium;propan-2-olate Chemical compound [K+].CC(C)[O-] WQKGAJDYBZOFSR-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/353—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by isomerisation; by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
全反式维甲酸的合成方法,以[3‑甲基‑5‑(2,6,6‑三甲基环己烯‑1‑基)‑2,4‑戊二烯]‑三苯基膦盐和β‑甲酰基巴豆酸为原料,在碱作用下发生WITTIG反应,然后加入钯化合物或铑化合物直接进行异构化反应,即得到所需全反式构型的产物。本方法反应的中间产物不需分离,且WITTIG反应和异构化反应这两步反应在一个容器中连续进行,操作简便,节约生产成本,适于工业化生产。
Description
技术领域:
本发明涉及一种全反式维甲酸的合成方法,具体涉及3,7-二甲基-9-(2,6,6-三甲基环己烯-1-基)-2,4,6,8全反式壬四烯酸的一种制备方法。
发明背景:
3,7-二甲基-9-(2,6,6-三甲基环己烯-1-基)-2,4,6,8全反式壬四烯酸(式I化合物)是维生素A的代谢中间产物,广泛应用于银屑病和痤疮的治疗;目前又是治疗急性早幼粒细胞白血病、骨髓异常增生的首选药物。
因为式I化合物中的壬四烯酸呈全反式构型,所以在制备时很容易产生多种异构体,如式IV的顺式异构体,所以式I化合物的合成方法中,很重要之处就是要控制产物的构型,要将所得顺式异构体有效的转化为全反式产品,同时又不能造成过大的损失,否则制备成本会非常高。
许多文献公开的制备式I化合物的方法是以[3-甲基-5-(2,6,6-三甲基环己烯-1-基)-2,4-戊二烯]-三苯基膦盐(式II)与β-甲酰基巴豆酸酯(式V)为原料,发生WITTIG反应,再经水解处理得到,如文献DE1059900等。但因为WITTIG反应会产生其顺式异构体,即产物中非全反式壬四烯酸的异构体含量较多(所需的全反式产品只有60-70%,而顺式异构体占30-40%)。而且合成方法较繁琐,收率较低。需重结晶2次,其收率只有25-30%,成本高。
式V中R为C1-C4的烷烃链。
文献CN101774954A用三步进行制备:
1、以[3-甲基-5-(2,6,6-三甲基环己烯-1-基)-2,4-戊二烯]-三苯基膦盐(式II)为原料,与β-甲酰基巴豆酸酯(式V)发生WITTIG反应,生成中间产物3,7-二甲基-9-(2,6,6-三甲基环己烯-1-基)-2,4,6,8全反式壬四烯酸酯(式VI)和其顺式异构体(式VII)的混合物;
2、将上述中间产物进行水解,处理后得到混酸;
3、将上述混酸再进行异构化转型,得到终产物式I。
此方法虽可解决产品的立体异构纯度问题,得到全反式的所需产物。但该方法步骤较多,存在中间的分离步骤,操作较复杂,需要较多工时,并造成产品的损失。特别是在水解步骤中,耗时且不彻底,因此成本较高,而总收率最高只能达到75%。
因此,亟需有一种合成方法简便,而且产物中全反式壬四烯酸的异构体含量高的的制备方法。
发明内容:
本发明的目的是寻找一种成本低,收率高,操作步骤少且简便,易于工业化生产3,7-二甲基-9-(2,6,6-三甲基环己烯-1-基)-2,4,6,8全反式壬四烯酸(式I化合物)的方法。
本发明提供的方法为:
式I化合物的制备方法,以[3-甲基-5-(2,6,6-三甲基环己烯-1-基)-2,4-戊二烯]-三苯基膦盐(式II)和β-甲酰基巴豆酸(式III)为原料,在碱作用下发生WITTIG反应;然后加入钯化合物或铑化合物进行异构化反应,得到所需构型的产物式I;其特征为:
1)WITTIG反应后不进行水解;
2)WITTIG反应的产物不需分离,直接进行异构化反应,且WITTIG反应和异构化反应这两步反应在一个容器中连续进行;
3)异构化反应前加酸调节反应液的pH值至5~10;
4)通过高效液相色谱方法监测异构化反应完成情况;
式II中X选自Cl,Br或HSO4。
上述反应原料中,式II化合物与式III化合物的摩尔比为1∶0.8~1.5;式II化合物可根据US3932485的方法制得;
所述碱为C1-C6烷醇的碱金属盐或金属氢氧化物,如甲醇钠,甲醇钾,甲醇锂,乙醇钠,乙醇钾,异丙醇钾,叔丁醇钾,氢氧化钠,氢氧化钾,氢氧化锂等,优选氢氧化钾。
所述WITTIG反应的温度为-50~30℃,优选反应温度为-5~5℃。所述WITTIG反应的反应时间为1~24小时,优选反应时间为3~4小时。
本发明人通过实验发现,进行异构化前,反应体系的pH值对下一步的异构化的转化率极为重要,pH值太低会影响转型,太高又易产生杂质。因此,在这个步骤控制pH值的范围是提高转化率,实现产品高收率的关键。
异构化前,通过加酸可严格控制所需要的pH值;所述酸是无机酸或有机酸,其中无机酸选自硫酸,盐酸,磷酸,氢溴酸等;有机酸是C1-C6的烷基酸,如甲酸,乙酸,丙酸,丁酸等,优选盐酸;酸的用量为调节反应体系的pH值为5~10,优选pH值7~8。
异构化反应的要求是使所得顺式异构体有效的转化为全反式产品。
本发明所使用的异构化反应的催化剂是钯或铑的化合物,选自PdCl2,PdBr2,PdI2,PdF2,PdS,(CH3CN)2PdCl2,Pd(OAc)2,(PhCN)2PdCl2,Pd(NO3)4(NH4)2,Pd(NH3)2Cl2,,PdS2,,K2PdCl6,Pd(NH3)2(NO2)2,Pd(NO2)4(NH3)2,(PhCN)2PdBr2,(NH4)2PdCl4,(NH4)2PdCl6,(Ph3P)4Pd(0),(Et3P)4Pd(0),(Ph3P)3PdCl2,Pd(NO3)2+Ph3P,铑与钯相同的盐或复合物也能被利用。Pd(OAc)2效果较好。所述钯或铑的化合物包括含钯或铑的复合物
所述钯或铑的化合物的用量与式II化合物的摩尔比为0.0001~0.02∶1。
异构化的温度对于异构化反应也有影响,温度低,异构化的速度慢;温度高,异构化的速度快,但杂质容易增多。优选的异构化温度是30℃~80℃,更优选50℃~6)℃。
异构化的时间没有特定限制,可通过高效液相色谱(HPLC)方法监测反应直到异构化反应完成。其标准是经HPLC检测,未异构化物料相对比例小于3%。
监测异构化反应高效液相色谱(HPLC)方法如下:色谱柱:Waters ODS(4.6×150mm,3μm),流动相:甲醇∶水∶冰乙酸=800∶225∶5;流速:1ml/min,柱温:30℃,检测波长:355;
异构化反应完成后,可通过倾入水中,酸中和,抽滤得粗品,经结晶得到产品。
用本方法制备式I化合物,通过使用β-甲酰基巴豆酸(式III),WITTIG反应后不需再水解,直接异构化,且两步串联,得到产品。与现有技术相比,不仅简化了步骤,免去了中间的分离单元,减少了工时和产品的损失,还通过严格的控制过程中的pH值,更进一步的增加了收率(总收率可达到85%),提高了生产效率,降低成本达40%,更适合于工业化生产。
表1本发明方法与现有技术方法比较
因此本发明提供了一种制备3,7-二甲基-9-(2,6,6-三甲基环己烯-1-基)-2,4,6,8全反式壬四烯酸的方法,该方法步骤短,操作简便,成本低,总收率高,生产效率高,能满足大规模生产的需要。
具体实施方式
实施例13,7-二甲基-9-(2,6,6-三甲基环己烯-1-基)-2,4,6,8全反式壬四烯酸的制备
186g的[3-甲基-5-(2,6,6-三甲基环己烯-1-基)-2,4-戊二烯]-三苯基膦氯盐溶于异丙醇500ml中,通氮气下加入42.3g的β-甲酰基巴豆酸,搅拌到溶液澄清,降温到-5℃,滴加浓度为2N KOH异丙醇溶液571ml,保持温度在-5℃,反应2小时,然后用盐酸调节pH值到7-8,加入86mg醋酸钯,升温到50℃,通过高效液相色谱(HPLC)检测反应结果,异构化反应完成后,倾入水中,加浓盐酸中和,抽滤即得粗品,经乙酸乙酯结晶得产品95.2g,纯度99.7%,收率85.3%。
实施例2、3及对比试验例1、2——不同的异构化pH条件
改变盐酸调节的pH值,其它按照实施例1的条件与方法进行,所得结果如下表:
盐酸中和pH值 | 产品纯度(%) | 收率(%) | |
实施例1 | 7-8 | 99.7 | 85.3 |
实施例2 | 5-6 | 99.4 | 84.6 |
实施例3 | 8.5-10 | 99.0 | 82.4 |
比试验例1 | 4.5-5 | 99.2 | 74.1 |
比试验例2 | 11.5-12 | 93.9 | 68.3 |
结论:异构化反应的pH值在5~10产品纯度好,收率较高。
实施例4~7——不同异构化催化剂
按照实施例1的条件进行,只是改变催化剂的种类,所得结果如下表:
实施例 | 催化剂 | 产品纯度(%) | 收率(%) |
4 | Pd(OAc)2 | 99.7 | 85.3 |
5 | (Ph3P)3PdCl2 | 99.4 | 83.5 |
6 | (PhCN)2PdBr2 | 99.3 | 84.2 |
7 | PdCl2 | 99.3 | 83.7 |
结论:几种异构化催化剂效果都很好,所得产物纯度好,收率较高。
实施例8-10及对比试验例4——不同异构化温度
按照实施例1的条件进行,只是改变异构化反应的温度,所得结果如下表:
温度(℃) | 产品纯度(%) | 收率(%) | |
实施例1 | 50 | 99.7 | 85.3 |
实施例8 | 30 | 99.5 | 84.3 |
实施例9 | 60 | 99.5 | 85.1 |
实施例10 | 70 | 99.3 | 82.4 |
对比试验例4 | 90 | 98.9 | 70.5 |
结论:异构化反应的适宜温度在50~70℃。
Claims (4)
1.式I化合物的制备方法,以[3-甲基-5-(2,6,6-三甲基环己烯-1-基)-2,4-戊二烯]-三苯基膦盐(式Ⅱ)和β-甲酰基巴豆酸(式Ⅲ)为原料,在碱作用下发生WITTIG反应,然后加入钯化合物进行异构化反应,得到所需全反式构型的产物式I;
其特征为:
1)WITTIG反应后不进行水解;
2)WITTIG反应的产物不需分离,直接进行异构化反应,且WITTIG反应和异构化反应这两步反应在一个容器中连续进行;
3)异构化反应前加酸调节反应液的pH值至5~10;
4)式Ⅱ化合物与式Ⅲ化合物用量的摩尔比为1∶0.8~1.5;
5)所述碱为C1~C6烷醇的碱金属盐或金属氢氧化物;
式Ⅱ中X选自Cl,Br或HSO4;
所述酸选自硫酸,盐酸,磷酸,氢溴酸、C1-C6的烷基酸;
所述钯化合物选自PdCl2,PdBr2,PdI2,PdF2,PdS,(CH3CN)2PdCl2,Pd(OAc)2,(PhCN)2PdCl2,Pd(NO3)4(NH4)2,Pd(NH3)2Cl2,PdS2,K2PdCl6,Pd(NH3)2(NO2)2,(PhCN)2PdBr2,(NH4)2PdCl4,(NH4)2PdCl6,(Ph3P)4Pd(0),(Et3P)4Pd(0),(Ph3P)3PdCl2,Pd(NO3)2+Ph3P;钯化合物与式Ⅱ化合物用量的摩尔比为0.0001~0.02∶1;
异构化反应的温度是30℃~80℃;
异构化反应完成是使顺式异构体转化为全反式产物,经高效液相色谱方法检测,未异构化物料相对比例小于3%;
所述高效液相色谱监测异构化反应的条件如下:色谱柱:Waters ODS,规格为4.6×150mm,3μm;流动相:甲醇∶水∶冰乙酸=800:225:5;流速:1ml/min;柱温:30℃;检测波长:355。
2.根据权利要求1所述的方法,异构化反应前加酸调节反应液的pH值至7~8。
3.根据权利要求1所述的方法,所述钯化合物是醋酸钯。
4.根据权利要求1或3所述的方法,异构化反应的温度是50℃~60℃。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110124227.3A CN102775338B (zh) | 2011-05-13 | 2011-05-13 | 全反式维甲酸合成方法 |
PCT/CN2012/075130 WO2012155796A1 (zh) | 2011-05-13 | 2012-05-07 | 一种定向合成维甲酸类化合物的方法 |
AU2012255352A AU2012255352B2 (en) | 2011-05-13 | 2012-05-07 | Stereospecific synthesis process for tretinoin compounds |
EP12786430.4A EP2708530B1 (en) | 2011-05-13 | 2012-05-07 | Stereospecific synthesis process for tretinoin compounds |
US14/117,343 US8835680B1 (en) | 2011-05-13 | 2012-05-07 | Stereospecific synthesis process for tretinoin compounds |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110124227.3A CN102775338B (zh) | 2011-05-13 | 2011-05-13 | 全反式维甲酸合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102775338A CN102775338A (zh) | 2012-11-14 |
CN102775338B true CN102775338B (zh) | 2016-09-21 |
Family
ID=47120472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110124227.3A Active CN102775338B (zh) | 2011-05-13 | 2011-05-13 | 全反式维甲酸合成方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8835680B1 (zh) |
EP (1) | EP2708530B1 (zh) |
CN (1) | CN102775338B (zh) |
AU (1) | AU2012255352B2 (zh) |
WO (1) | WO2012155796A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104086472A (zh) * | 2014-06-17 | 2014-10-08 | 重庆华邦胜凯制药有限公司 | 一种制备13-顺维甲酸的方法 |
US9919993B2 (en) | 2014-09-17 | 2018-03-20 | Emcure Pharmaceuticals Limited | Process for preparation of acitrecin |
CN106483202B (zh) * | 2015-08-25 | 2021-03-30 | 重庆华邦制药有限公司 | 一种分离和测定阿利维a酸与异构体的方法 |
CN111423348B (zh) * | 2020-04-26 | 2021-10-22 | 上海新华联制药有限公司 | 一种异维a酸及其制备方法和应用 |
CN114105737A (zh) * | 2021-11-24 | 2022-03-01 | 重庆华邦胜凯制药有限公司 | 一种阿维a的中间体的制备方法及其应用 |
CN116217453B (zh) * | 2023-01-03 | 2024-02-02 | 万华化学集团股份有限公司 | 一种β-阿朴-8’-胡萝卜素醛的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1068710B (de) * | 1958-08-06 | 1959-11-12 | Badische Anilin- &. Soda-Fabrik Aktiengesellschaft, Ludwigshafen/Rhein | Verfahren zur Herstellung von Verbindungen der beta-Ionylidenäthyliden-Reihe |
US4556518A (en) * | 1982-12-10 | 1985-12-03 | Hoffmann-La Roche Inc. | Preparation of 13-cis retinoic acid |
CN101774954A (zh) * | 2009-01-12 | 2010-07-14 | 重庆胜凯科技有限公司 | 全反式维甲酸的制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1059900B (de) | 1957-09-03 | 1959-06-25 | Basf Ag | Verfahren zur Herstellung von Verbindungen der Vitamin A-Reihe |
US3932485A (en) | 1974-08-28 | 1976-01-13 | Hoffmann-La Roche Inc. | Improved preparation of Wittig salt of vinyl β-ionol |
US4215215A (en) | 1975-08-01 | 1980-07-29 | Hoffmann-La Roche Inc. | 9-Phenyl-nonate traene compounds |
DE4344148A1 (de) | 1993-12-23 | 1995-08-24 | Basf Ag | Verfahren zur Herstellung von 9-(Z)-Retinsäure |
PL1615879T3 (pl) * | 2003-04-11 | 2015-02-27 | Glaxo Group Ltd | Sposób wytwarzania kwasu 9-cis-retinowego |
CN101987840B (zh) | 2009-08-05 | 2012-07-25 | 重庆华邦制药股份有限公司 | 一种5-羟基-4-甲基-2-5[h]-呋喃酮的分离方法 |
-
2011
- 2011-05-13 CN CN201110124227.3A patent/CN102775338B/zh active Active
-
2012
- 2012-05-07 US US14/117,343 patent/US8835680B1/en active Active
- 2012-05-07 WO PCT/CN2012/075130 patent/WO2012155796A1/zh active Application Filing
- 2012-05-07 AU AU2012255352A patent/AU2012255352B2/en active Active
- 2012-05-07 EP EP12786430.4A patent/EP2708530B1/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1068710B (de) * | 1958-08-06 | 1959-11-12 | Badische Anilin- &. Soda-Fabrik Aktiengesellschaft, Ludwigshafen/Rhein | Verfahren zur Herstellung von Verbindungen der beta-Ionylidenäthyliden-Reihe |
US4556518A (en) * | 1982-12-10 | 1985-12-03 | Hoffmann-La Roche Inc. | Preparation of 13-cis retinoic acid |
CN101774954A (zh) * | 2009-01-12 | 2010-07-14 | 重庆胜凯科技有限公司 | 全反式维甲酸的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2708530A1 (en) | 2014-03-19 |
EP2708530A4 (en) | 2014-12-31 |
AU2012255352B2 (en) | 2015-07-23 |
CN102775338A (zh) | 2012-11-14 |
EP2708530B1 (en) | 2016-08-10 |
US20140275617A1 (en) | 2014-09-18 |
WO2012155796A1 (zh) | 2012-11-22 |
US8835680B1 (en) | 2014-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102775338B (zh) | 全反式维甲酸合成方法 | |
CN108752251B (zh) | 一种全反式β-胡萝卜素的制备方法 | |
CN110903190B (zh) | 一种维生素a及维生素a酯的制备方法 | |
KR102271364B1 (ko) | 신규화합물 Potassium all-trans retinoate 및 Potassium 9-cis retinoate의 합성방법 | |
CN101219983B (zh) | 一种改进的维生素a乙酸酯的制备方法 | |
CN110950791B (zh) | 一种维生素a及维生素a酯制备方法 | |
CN104086472A (zh) | 一种制备13-顺维甲酸的方法 | |
CN109232184B (zh) | 一种通过手性拆分提高l-异胡薄荷醇光学纯度的方法 | |
CN108610252B (zh) | 阿维a酸异构化的新方法 | |
CN103058850B (zh) | 一种制备阿利维甲酸的方法 | |
CN103880740A (zh) | 4-硝基-3-羟基-2-吡啶甲酸的合成 | |
CN102120726B (zh) | 一种制备(2e)-2-氰基-3-(3,4-二羟基-5-硝基苯)-n,n-二乙基-2-丙烯酰胺的新方法 | |
CN102627520B (zh) | 用于在有硫脲存在时异构化番茄红素的方法 | |
CN102924276B (zh) | 2-甲基-2-乙酰氧基-3-丁烯-1-醛的制备方法及其中间体半缩醛 | |
CN113292468A (zh) | 一种全反式β-胡萝卜素的制备方法 | |
CN101381311A (zh) | 5-硝基-2,4-二卤代苯酚类化合物的制备方法 | |
CN102311339B (zh) | 一种4-乙酰氧基-2-甲基-2-丁烯-1-醛的制备方法 | |
CN107793330B (zh) | 一种安塞曲匹手性中间体的合成方法 | |
CN104370987A (zh) | 一种卤米松的精制方法 | |
CN109761894A (zh) | 一种5-溴-2-吡啶甲酸的制备方法 | |
CN116462621A (zh) | 一种维a酸的制备方法 | |
CN103641727A (zh) | 一种羟萘酸沙美特罗的制备方法 | |
CN110156716B (zh) | 一种苯并噻唑酯类衍生物的合成方法 | |
CN101851153B (zh) | 烯丙位氧化制备2-(6’-甲氧基-2’-萘基)烯丙醇的方法 | |
CN107056587B (zh) | 一种合成l-薄荷脑的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |